Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

NCT03173560 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

343

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: lenvatinib
DRUG: everolimus

Sponsor

Eisai Inc.

Collaborators

[object Object]